Turkish Journal of Gastroenterology
Poster

Thyroid manifestations in autoimmune liver diseases: a single center experience

1.

Department of Gastroenterology, Goztepe ERH, Medeniyet University, Istanbul, Turkey

2.

Department of Endocrinlogy, Goztepe ERH, Medeniyet University, Istanbul, Turkey

3.

Department of Radiology, Goztepe ERH, Medeniyet University, Istanbul, Turkey

Turk J Gastroenterol 2019; 30: Supplement 89-90
DOI: 10.5152/tjg.2019.59
Read: 1816 Downloads: 574 Published: 25 July 2019

Abstract

 

INTRODUCTION: Thyroid diseases may be seen in various autoimmune and viral liver diseases related to autoimmunity, complications, drugs and other treatment modalities. Revised International Autoimmune Hepatitis Group score adds 2 points for accompanying thyroiditis or another autoimmune disease presence (1,2,3). In this study we aimed to assess the thyroid findings in autoimmune liver diseases (AILD) patients including Autoimmune Hepatitis (AIH), Primary Biliary Cholangitis (PBC), Overlap Syndromes and Primary Sclerosing Cholangitis (PSC). We aimed to assess the thyroid pathologies in our AILD cohort.

METHODS: Patients with AILD under follow-up in gastroenterology department of a tertiary hospital (Istanbul Medeniyet University, Goztepe Education and Research Hospital, Istanbul,Turkey) were investigated with palpation, thyroid function tests, autoantibodies and thyroid ultrasonography. The demographic and laboratory data were statistically analysed. 

RESULTS: The total registered patients in a single center with AILD were 111 (101 female and 10 male; 55 PBC, 44 AIH, 10 Overlap and 2 PSC) fulfilling relevant criteria for their diagnosis. The mean age of the patients was 56,4±13,6 (23-84). Of these,13 patients had died previously related to liver problems. Of these 98 patients,Hashimoto thyroiditis (21.4%), Hypothyroidia (10%) and Basedow-Graves disease (3.0%) were assessed (Table 1). Thyroid ultrasonography revealed 74.3% had heterogenous parenchyma and 28% had thyroid nodüle(s). One patient had papillary carcinoma which later treated appropriately. Nineteen patients (19.4%) were receiving L-thyroxin. 

CONCLUSION: In our AILD patients, thyroid findings were primarily Hashimoto’s thyroiditis and heterogenous parenchyma. Incidentally a thyroid papillary carcinoma was detected and treated appropriately. There was no difference between subgroups by means of thyroiditis and parenchymal heterogenity. Treatment response and clinical severity were not related with thyroid manifestations. Intermittent controls of thyroid gland in AILD patients may be crucial to detect thyroid pathologies before advanced disease. 

Files
EISSN 2148-5607